These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 12736725

  • 1. Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma.
    Kim R, Tanabe K, Uchida Y, Emi M, Toge T.
    Int J Mol Med; 2003 Jun; 11(6):799-804. PubMed ID: 12736725
    [Abstract] [Full Text] [Related]

  • 2. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
    Tanabe K, Kim R, Inoue H, Emi M, Uchida Y, Toge T.
    Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
    [Abstract] [Full Text] [Related]

  • 3. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R, Tanabe K, Emi M, Uchida Y, Osaki A, Toge T.
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [Abstract] [Full Text] [Related]

  • 4. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
    Kim R, Tanabe K, Inoue H, Toge T.
    Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567
    [Abstract] [Full Text] [Related]

  • 5. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
    Sawada S, Mese H, Sasaki A, Yoshioka N, Matsumura T.
    Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
    [Abstract] [Full Text] [Related]

  • 6. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells.
    Kim R, Tanabe K, Emi M, Uchida Y, Toge T.
    Cancer; 2005 May 15; 103(10):2199-207. PubMed ID: 15830342
    [Abstract] [Full Text] [Related]

  • 7. Co-transfection of MRP and bcl-2 antisense S-oligodeoxynucleotides reduces drug resistance in cisplatin-resistant lung cancer cells.
    Wang J, Liu X, Jiang W.
    Chin Med J (Engl); 2000 Oct 15; 113(10):957-60. PubMed ID: 11775848
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma.
    Kausch I, Jiang H, Thode B, Doehn C, Krüger S, Jocham D.
    Eur Urol; 2005 May 15; 47(5):703-9. PubMed ID: 15826766
    [Abstract] [Full Text] [Related]

  • 9. Cyclin D1 overexpression induces epidermal growth factor-independent resistance to apoptosis linked to BCL-2 in human A431 carcinoma.
    Rieber M, Rieber MS.
    Apoptosis; 2006 Jan 15; 11(1):121-9. PubMed ID: 16374552
    [Abstract] [Full Text] [Related]

  • 10. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.
    Zangemeister-Wittke U, Leech SH, Olie RA, Simões-Wüst AP, Gautschi O, Luedke GH, Natt F, Häner R, Martin P, Hall J, Nalin CM, Stahel RA.
    Clin Cancer Res; 2000 Jun 15; 6(6):2547-55. PubMed ID: 10873111
    [Abstract] [Full Text] [Related]

  • 11. Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma.
    Kim R, Emi M, Tanabe K, Toge T.
    Cancer; 2004 Nov 15; 101(10):2177-86. PubMed ID: 15476281
    [Abstract] [Full Text] [Related]

  • 12. Role of intracellular glutathione in cell sensitivity to the apoptosis induced by tumor necrosis factor {alpha}-related apoptosis-inducing ligand/anticancer drug combinations.
    Meurette O, Lefeuvre-Orfila L, Rebillard A, Lagadic-Gossmann D, Dimanche-Boitrel MT.
    Clin Cancer Res; 2005 Apr 15; 11(8):3075-83. PubMed ID: 15837763
    [Abstract] [Full Text] [Related]

  • 13. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
    Brenes O, Arce F, Gätjens-Boniche O, Díaz C.
    Biomed Pharmacother; 2007 Jul 15; 61(6):347-55. PubMed ID: 17399942
    [Abstract] [Full Text] [Related]

  • 14. Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments.
    Sun B, Moibi JA, Mak A, Xiao Z, Roa W, Moore RB.
    J Urol; 2009 Mar 15; 181(3):1361-71. PubMed ID: 19157446
    [Abstract] [Full Text] [Related]

  • 15. Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma.
    Bravo SB, García-Rendueles ME, Seoane R, Dosil V, Cameselle-Teijeiro J, López-Lázaro L, Zalvide J, Barreiro F, Pombo CM, Alvarez CV.
    Clin Cancer Res; 2005 Nov 01; 11(21):7664-73. PubMed ID: 16278386
    [Abstract] [Full Text] [Related]

  • 16. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP].
    Li M, Yu LL, Cai LQ, Wang HB, Wang ZH, Wang ZH.
    Zhonghua Fu Chan Ke Za Zhi; 2006 Feb 01; 41(2):121-5. PubMed ID: 16640863
    [Abstract] [Full Text] [Related]

  • 17. The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma.
    Duggan BJ, Maxwell P, Kelly JD, Canning P, Anderson NH, Keane PF, Johnston SR, Williamson KE.
    J Urol; 2001 Sep 01; 166(3):1098-105. PubMed ID: 11490306
    [Abstract] [Full Text] [Related]

  • 18. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10.
    Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di Liberto D, Patti M, Florena A, Di Gaudio F, Di Gesù G, De Maria R.
    Cancer Res; 2003 Oct 15; 63(20):6784-90. PubMed ID: 14583474
    [Abstract] [Full Text] [Related]

  • 19. Glycerol enhances CDDP-induced growth inhibition of thyroid anaplastic carcinoma tumor carrying mutated p53 gene.
    Yuki K, Takahashi A, Ota I, Ohnishi K, Yasumoto J, Kanata H, Yane K, Hosoi H, Ohnishi T.
    Oncol Rep; 2004 Apr 15; 11(4):821-4. PubMed ID: 15010879
    [Abstract] [Full Text] [Related]

  • 20. [Therapeutic potential of antisense (AS) Bcl-2 as a chemosensitizer for patients with gastric and breast carcinoma].
    Kim R, Emi M, Matsuura K, Tanabe K.
    Gan To Kagaku Ryoho; 2005 Oct 15; 32(11):1540-5. PubMed ID: 16315863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.